Developing Policy for the Healthy Life Trajectories Initiative: Going from National to International

Background: Scientific research is becoming an increasingly collaborative and global venture. The Healthy Life Trajectories Initiative (HeLTI), for instance, is an international Developmental Origins of Health and Disease research collaboration developed to address the increasing burden of noncommunicable diseases around the world. It comprises four separate but harmonized cohort trials in Canada, China, India, and South Africa. These cohorts will generate rich data and biosample sets that can be shared both within the HeLTI Consortium and with other researchers from around the world. Methods: To ensure the coordination and operation of these types of collaborative research initiatives, a standardized and harmonized governance model is required to regulate the processes and interactions between all involved actors. To develop the governance models, frameworks and related policies from other longitudinal cohort studies and biobanks were used, as were guidance documents on biobank and database governance and relevant literature on data and biobank governance. Results: This article outlines the key components of the governance model for the HeLTI Consortium, including management of the cohorts' respective databases and biobanks, access to data and biosamples, and considerations related to intellectual property and publications. Conclusion: Governance within international collaborative research ventures is critical to ensure the operations and benefits of these types of research apparatuses. Although this article focuses on the HeLTI Consortium as a model, it may nonetheless serve as a model for both current and future collaborative consortium-based research initiatives. Clinical Trial Registration Numbers: Canada, ISRCTN13308752; China, ChiCTR1800017773; India, ISRCTN20161479; South Africa, PACTR201903750173871.

[1]  C. Dennis,et al.  Building knowledge, optimising physical and mental health and setting up healthier life trajectories in South African women (Bukhali): a preconception randomised control trial part of the Healthy Life Trajectories Initiative (HeLTI) , 2022, BMJ Open.

[2]  B. Knoppers,et al.  Study protocol for the Sino-Canadian Healthy Life Trajectories Initiative (SCHeLTI): a multicentre, cluster-randomised, parallel-group, superiority trial of a multifaceted community-family-mother-child intervention to prevent childhood overweight and obesity , 2021, BMJ Open.

[3]  P. Szatmari,et al.  Protocol for a randomised trial evaluating a preconception-early childhood telephone-based intervention with tailored e-health resources for women and their partners to optimise growth and development among children in Canada: a Healthy Life Trajectory Initiative (HeLTI Canada) , 2021, BMJ Open.

[4]  C. Dennis,et al.  Protocol for a cluster randomised trial evaluating a multifaceted intervention starting preconceptionally—Early Interventions to Support Trajectories for Healthy Life in India (EINSTEIN): a Healthy Life Trajectories Initiative (HeLTI) Study , 2021, BMJ Open.

[5]  C. Greenwood,et al.  Maternal Prenatal Mood, Pregnancy-Specific Worries, and Early Child Psychopathology: Findings From the DREAM BIG Consortium. , 2020, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  S. Kalkman,et al.  Responsible data sharing in international health research: a systematic review of principles and norms , 2019, BMC medical ethics.

[7]  Ma'n Zawati,et al.  The author who wasn’t there? Fairness and attribution in publications following access to population biobanks , 2018, PLoS ONE.

[8]  A. Calderón-Larrañaga,et al.  Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study , 2018, International journal of epidemiology.

[9]  Bartha Maria Knoppers,et al.  Ethics and Big Data in health , 2017 .

[10]  Christine M. Cutillo,et al.  The importance of international collaboration for rare diseases research: a European perspective , 2017, Gene Therapy.

[11]  Daniel Strech,et al.  Access policies in biobank research: what criteria do they include and how publicly available are they? A cross-sectional study , 2016, European Journal of Human Genetics.

[12]  B. Knoppers,et al.  Access Governance for Biobanks: The Case of the BioSHaRE-EU Cohorts , 2016, Biopreservation and Biobanking.

[13]  Howard Bauchner,et al.  Data Sharing: An Ethical and Scientific Imperative. , 2016, JAMA.

[14]  M. Mostert,et al.  Data sharing in stem cell translational science: policy statement by the International Stem Cell Forum Ethics Working Party. , 2015, Regenerative medicine.

[15]  Pascal Borry,et al.  From the principles of genomic data sharing to the practices of data access committees , 2015, EMBO molecular medicine.

[16]  B. Lo Sharing clinical trial data: maximizing benefits, minimizing risk. , 2015, JAMA.

[17]  Sara Chandros Hull,et al.  Identifiability and privacy in pluripotent stem cell research. , 2014, Cell stem cell.

[18]  Haidan Chen,et al.  Governing International Biobank Collaboration: A Case Study of China Kadoorie Biobank , 2013 .

[19]  R. Gallagher,et al.  From consent to institutions: designing adaptive governance for genomic biobanks. , 2011, Social science & medicine.

[20]  Jane Kaye,et al.  From single biobanks to international networks: developing e-governance , 2011, Human Genetics.

[21]  M. Krawczak,et al.  Biobanking and international interoperability: samples , 2011, Human Genetics.

[22]  M. Mottolese,et al.  Minimum biobanking requirements: issues in a comprehensive cancer center biobank. , 2011, Biopreservation and biobanking.

[23]  Hans Hillege,et al.  Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies , 2010, International journal of epidemiology.

[24]  K. O’Doherty,et al.  Biobank governance: a lesson in trust , 2010 .

[25]  J. Carlstedt-Duke,et al.  Building global networks for human diseases: genes and populations , 2004, Nature Medicine.